Redburn Atlantic analyst Issie Kirby upgraded Alcon to Neutral from Sell with a price target of CHF 78, up from CHF 68. The firm sees sustainable surgical revenue growth acceleration on back of the company’s new equipment upgrade cycle. While the U.S. cataract market remains soft, competitive pressures in premium intraocular lenses are alleviated by Alcon’s new PanOptix launches in the mid-term, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC: